Nasdaq threatens to delist Miragen for low stock price
BOULDER — The Nasdaq is threatening to kick Miragen Therapeutics Inc. (Nasdaq: MGEN) off the public markets if it doesn’t improve its stock price, right after the company kicked off a possible $5 million private stock offering deal with a cancer nonprofit.
The Boulder oncology drugmaker disclosed that the second-largest stock market in the United States sent a letter to the company earlier this week saying that its stock price was below $1 per share for the past 30 trading days, the threshold that companies must meet to stay listed.
Miragen has until April 27, 2020,…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Boulder-based publishing technology company Sovrn Holdings Inc. has named Will Duckworth its chief technology officer.
-
A Boulder fiber infrastructure company and broadband internet provider said it has raised $80 million…
-
Knowledge Factor Inc., a software-as-a-service company that provides cognitive science-based assessment, training and data analytics…
-
Tilled Inc., a Boulder payment-facilitation technology company, recently completed a $12.5 million investment round, bringing…
